RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS

Holly Spence,Fergal M. Waldron,Rebecca S. Saleeb,Anna-Leigh Brown,Olivia M. Rifai,Martina Gilodi,Fiona Read,Kristine Roberts,Gillian Milne,Debbie Wilkinson,Judi O’Shaughnessy,Annalisa Pastore,Pietro Fratta,Neil Shneider,Gian Gaetano Tartaglia,Elsa Zacco,Mathew H. Horrocks,Jenna M. Gregory

DOI: https://doi.org/10.1007/s00401-024-02705-1

IF: 15.887

2024-03-06

Acta Neuropathologica

Abstract:TDP-43 is an aggregation-prone protein which accumulates in the hallmark pathological inclusions of amyotrophic lateral sclerosis (ALS). However, the analysis of deeply phenotyped human post-mortem samples has shown that TDP-43 aggregation, revealed by standard antibody methods, correlates poorly with symptom manifestation. Recent identification of cryptic-splicing events, such as the detection of Stathmin-2 ( STMN-2 ) cryptic exons, are providing evidence implicating TDP-43 loss-of-function as a potential driving pathomechanism but the temporal nature of TDP-43 loss and its relation to the disease process and clinical phenotype is not known. To address these outstanding questions, we used a novel RNA aptamer, TDP-43 APT , to detect TDP-43 pathology and used single molecule in situ hybridization to sensitively reveal TDP-43 loss-of-function and applied these in a deeply phenotyped human post-mortem tissue cohort. We demonstrate that TDP-43 APT identifies pathological TDP-43, detecting aggregation events that cannot be detected by classical antibody stains. We show that nuclear TDP-43 pathology is an early event, occurring prior to cytoplasmic accumulation and is associated with loss-of-function measured by coincident STMN-2 cryptic splicing pathology. Crucially, we show that these pathological features of TDP-43 loss-of-function precede the clinical inflection point and are not required for region specific clinical manifestation. Furthermore, we demonstrate that gain-of-function in the form of extensive cytoplasmic accumulation, but not loss-of-function, is the primary molecular correlate of clinical manifestation. Taken together, our findings demonstrate implications for early diagnostics as the presence of STMN-2 cryptic exons and early TDP-43 aggregation events could be detected prior to symptom onset, holding promise for early intervention in ALS.

pathology,neurosciences,clinical neurology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is about the pathological role of TDP - 43 protein in amyotrophic lateral sclerosis (ALS) and its temporal relationship with the emergence of clinical symptoms. Specifically, the researchers focus on the following aspects:

1. **TDP - 43 Aggregation Events**: TDP - 43 is a protein prone to aggregation, and its aggregation is a hallmark pathological feature of ALS. However, the TDP - 43 aggregation detected by traditional antibody methods has a poor correlation with the appearance of symptoms. Therefore, the researchers developed a new RNA aptamer, named TDP - 43APT, to more sensitively detect the pathological changes of TDP - 43.

2. **Loss of TDP - 43 Function**: The loss of TDP - 43 function is considered an important aspect of the pathogenesis of ALS. The researchers evaluated the loss of TDP - 43 function by detecting the cryptic splicing event of Stathmin - 2 (STMN - 2). The cryptic splicing event of STMN - 2 is used as a molecular marker for the loss of TDP - 43 function.

3. **Temporal Sequence of TDP - 43 Pathological Changes**: The researchers hope to understand whether the intranuclear pathological changes of TDP - 43 occur earlier than the cytoplasmic aggregation, and whether these pathological changes precede the emergence of clinical symptoms.

4. **Gain of TDP - 43 Function**: In addition to the loss of function, the gain of TDP - 43 function (such as extensive cytoplasmic aggregation) is also considered an important pathological mechanism of ALS. The researchers hope to detect these gain - of - function changes through TDP - 43APT and evaluate their relationship with clinical symptoms.

Through these studies, the authors hope to better understand the role of TDP - 43 in the pathogenesis of ALS and the relationship between these pathological changes and clinical symptoms, thereby providing potential targets for early diagnosis and intervention.